M E Scheulen

Risk factors for venous thromboembolic events in cancer patients.

S Seeber, K Kröger, S. Seeber, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors.

R. Hilger, M. Scheulen, H. Richly, 2009, International journal of clinical pharmacology and therapeutics.

A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors.

S Seeber, C. Unger, D. Strumberg, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

M Büchert, M Jeffers, M. Büchert, 2012, British Journal of Cancer.

Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.

S Seeber, D. Strumberg, S. Seeber, 2003, International journal of clinical pharmacology and therapeutics.

Drug- and radiation-induced resistance in a human neurogenic sarcoma xenografted in nude mice.

W Budach, V Budach, M E Scheulen, 1993, Cancer chemotherapy and pharmacology.